EUFEST STUDY PDF

EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Tosar Grozil
Country: Zambia
Language: English (Spanish)
Genre: Marketing
Published (Last): 22 December 2005
Pages: 88
PDF File Size: 1.13 Mb
ePub File Size: 2.66 Mb
ISBN: 673-8-46488-496-2
Downloads: 58053
Price: Free* [*Free Regsitration Required]
Uploader: Zolok

We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries. Schizophreniform or schizoaffective disorder; 3. The primary outcome measure is retention in treatment, eurest as time to discontinuation of study drug.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Natural history of schizophrenia. Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone. The primary outcome measure was all-cause treatment discontinuation. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.

Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

At regular time intervals patients are followed-up until 12 months after recruitment: Evid Based Ment Health.

We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment.

  LUKES STEVEN - EMILE DURKHEIM SU VIDA Y OBRA PDF

This outcome is sstudy at regular time intervals until 12 months after recruitment. Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Eligibility Participant inclusion criteria 1.

Rationale and design of the trial. Home Who are we? At present, more than patients have been recruited and randomized in the following countries: Result of results found for within. Intolerance to one of the drugs in this study 4. Diagnosis of schizophrenia; 2. Genetic determinants of response to antipsychotic drugs 9.

This effort represents the first independently designed trans-European schizophrenia treatment trial. Results and Publications Publication and dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1.

These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics. Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients. The European study of eifest effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia. Ethics approval received from the local medical ethics committee. The presence of one eufesr more of the contraindications against any of the study drugs.

EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0. Multicentre, randomised active controlled, parallel group trial.

We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. euest

  HK416 MANUAL PDF

This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year. Analysis was by intention to treat.

Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. At regular time intervals patients are followed-up until 12 months after recruitment: The study should be finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics.

Previous Trial Back to results Next Trial. Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. Quality of life 6. Eligible patients were aged years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested. Intolerance to one of the drugs in this study; 4. Patients and their treating physicians were not blinded to the assigned treatment.